Dose Escalation Study of Nelfinavir Plus MLN9708 in Patients With Advanced Solid Tumors or Lymphoma

NCT03422874 · clinicaltrials.gov ↗

PHASE1

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped Sponsor withdrew support

Conditions

Neoplasms
Lymphoma

Interventions

DRUG: MLN9708
DRUG: Nelfinavir

Sponsor

Dartmouth-Hitchcock Medical Center